The journal retracts the article “Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Inhibitor as a Novel Therapeutic Tool for Lung Injury” [1] cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of images presented in this publication [1].
Adhering to our standard procedure, an investigation was conducted by the Editorial Office and Editorial Board that identified indications of inappropriate editing and partial duplication between micrographs in Figure 1C,D in this article [1]. While the authors collaborated within this process, raw material meeting the journals requirements for original images could not be provided for Editorial Board Evaluation. Consequently, the Editorial Board has lost confidence in the reliability of the findings and has decided to retract this publication, as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 9 March 2026).
This retraction was approved by the Editor-in-Chief of the International Journal of Molecular Sciences.
The authors disagreed with this retraction.
Reference
- Fusco, R.; Siracusa, R.; D’Amico, R.; Cordaro, M.; Genovese, T.; Gugliandolo, E.; Peritore, A.F.; Crupi, R.; Di Paola, R.; Cuzzocrea, S.; et al. RETRACTED: Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Inhibitor as a Novel Therapeutic Tool for Lung Injury. Int. J. Mol. Sci. 2020, 21, 7761. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.